RGENIX Announces Company Name Change to Inspirna and Expands Board of Directors with Appointment of Pharma Veteran Dieter Weinand
NEW YORK--(BUSINESS WIRE)--Inspirna, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and biologic cancer therapeutics, announced today its corporate name change from Rgenix to Inspirna and announced the appointment of Dieter Weinand to its Board of Directors, where
RGENIX to Present at Piper Sandler 32nd Annual Virtual Healthcare Conference
New York, NY – November 23, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 32nd Annual Piper Sandler Virtual
RGENIX to Present at 2020 Stifel Virtual Healthcare Conference
New York, NY – November 04, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that CEO Masoud Tavazoie, M.D., Ph.D., will present at the 2020 Stifel Virtual Healthcare Conference at 8:40 A.M. EST on November 16, 2020. To view this virtual presentation live, register for the event here. Links
RGENIX to Present at H.C. Wainwright 22nd Annual Global Investment Conference
New York, NY – September 02, 2020 - RGENIX, Inc., a clinical stage biopharmaceutical company developing first-in-class small molecule and antibody cancer therapeutics, announced today that it has been selected to present at the H.C. Wainwright 22nd Annual Global Investment